Sofinnova Investments related stories
All articles and analysis
Medeor Therapeutics scores $57 mln Series BSan Mateo, California-based Medeor Therapeutics Inc, a developer of personalized cellular immunotherapies, has raised $57 million in Series B financing. RA Capital Management led the round with participation from other investors that included Sofinnova Ventures, 6 Dimensions Capital, Vivo Capital and WuXi Healthcare Ventures. In conjunction with the financing, Dr. Peter Kolchinsky, a portfolio manager and managing director at RA Capital and Dr. Anand Mehra, general partner at Sofinnova Ventures, have joined the Medeor's board of directors.
- Entasis Therapeutics snags $31.9 mln
Waltham, Massachusetts-based Entasis Therapeutics, a developer of anti-infective products, has raised $31.9 million in funding. The investors were Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech. In conjunction with the funding, Dr. Tracy Saxton, managing partner at Pivotal, Dr. Heather Behanna, a principal at Sofinnova, and Dr. Heather Preston, a partner at TPG, have been added to the Entasis board of directors.
- VC-backed Synlogic and Mirna Therapeutics completes merger
Synlogic Inc and Mirna Therapeutics Inc have closed their previously announced merger. The newly combined company will operate under the Synlogic name and focus on developing medicines that treat metabolic and inflammatory diseases and cancer. Following the closing of the deal, the merged company has about $100 million in cash and cash equivalents. Also, Synlogic will start trading August 28, 2017 on the NASDAQ under the ticker symbol “SYBX." Synlogic's backers include Aju IB Investment, Ally Bridge Group, Arctic Aurora LifeScience, CLI Ventures, Perceptive Advisors, Rock Springs Capital, Atlas Venture, Deerfield, New Enterprise Associates and OrbiMed.
- Amplyx Pharmaceuticals racks up $67 mln Series C
San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $67 million in Series C financing. Sofinnova Venture Partners led the round with participation from other investors that included Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, New Enterprise Associates, RiverVest Venture Partners, 3x5 RiverVest II and BioMed Ventures. In conjunction with the financing, Dr. Anand Mehra, managing partner at Sofinnova Ventures, and Dr. Johan Kördel, senior partner at Lundbeckfonden Ventures, will join the Amplyx board of directors.
- BioClin Therapeutics inks $30 mln Series B
San Ramon, California-based drug developer BioClin Therapeutics Inc has secured $30 million in Series B financing. Sofinnova Ventures and Ysios Capital led the round with participation from other investors that included HealthCap, Life Sciences Partners and Tekla Capital Management.
- Sofinnova Ventures raises $650m
View the latest closings